BridgeBio Pharma’s (BBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO) in a report published on Wednesday, MarketBeat.com reports. HC Wainwright currently has a $120.00 price objective on the stock. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at $0.13 EPS, FY2026 earnings at ($1.88) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at $0.19 EPS, Q3 2027 earnings at $0.49 EPS, Q4 2027 earnings at $0.79 EPS and FY2027 earnings at $1.31 EPS.

BBIO has been the subject of a number of other reports. Weiss Ratings lowered BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Piper Sandler boosted their price objective on BridgeBio Pharma from $111.00 to $115.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Mizuho upped their target price on shares of BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a research report on Tuesday. Canaccord Genuity Group raised their target price on shares of BridgeBio Pharma from $104.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Citigroup lifted their price target on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Twenty investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $101.53.

BridgeBio Pharma Stock Performance

Shares of BBIO opened at $74.84 on Wednesday. The firm has a market capitalization of $14.63 billion, a price-to-earnings ratio of -20.96 and a beta of 0.97. The business’s fifty day moving average price is $80.74 and its two-hundred day moving average price is $73.62. BridgeBio Pharma has a 52 week low of $48.78 and a 52 week high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to the consensus estimate of $220.91 million. The business’s revenue for the quarter was up 120.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.95) earnings per share. As a group, research analysts forecast that BridgeBio Pharma will post -2.64 EPS for the current year.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, Director Jennifer Cook sold 148,589 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the transaction, the director owned 8,383 shares in the company, valued at approximately $742,230.82. This trade represents a 94.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 2,808 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $68.00, for a total value of $190,944.00. Following the transaction, the director owned 11,455 shares of the company’s stock, valued at $778,940. The trade was a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 347,343 shares of company stock valued at $27,591,000. Corporate insiders own 14.23% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in BridgeBio Pharma in the second quarter valued at approximately $715,000. California State Teachers Retirement System boosted its position in shares of BridgeBio Pharma by 7,463.2% during the second quarter. California State Teachers Retirement System now owns 12,532,377 shares of the company’s stock worth $933,411,000 after purchasing an additional 12,366,674 shares in the last quarter. Lionsbridge Wealth Management LLC bought a new position in shares of BridgeBio Pharma during the second quarter worth $704,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $289,000. Finally, Two Sigma Securities LLC acquired a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $1,317,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $120 price target, indicating that the analyst believes BridgeBio’s longer-term growth potential remains intact despite the earnings-estimate reductions. HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma
• Positive Sentiment: Barclays and Cantor Fitzgerald also maintained Buy ratings on BridgeBio Pharma, providing additional analyst support for the stock. Barclays Sticks to Its Buy Rating for BridgeBio Pharma Cantor Fitzgerald Remains a Buy on BridgeBio Pharma
• Neutral Sentiment: HC Wainwright’s estimates still imply a transition from losses in 2026 to profitability in 2027, forecasting a $1.88 per-share loss for fiscal 2026 and $1.31 in earnings for fiscal 2027.
• Negative Sentiment: HC Wainwright lowered its fiscal 2026 EPS forecast to a $1.88 loss from a $1.50 loss and cut its fiscal 2027 estimate to $1.31 from $2.19. It also reduced estimates for several 2027 quarters, including Q1 to a $0.18 loss from $0.11 in earnings and Q2 to $0.19 in earnings from $0.44.
• Negative Sentiment: The estimate cuts extend to near-term results: Q3 2026 EPS was lowered to a $0.40 loss from a $0.38 loss, while Q4 2026 EPS was trimmed slightly to $0.13 from $0.14. These revisions may weigh on sentiment because they point to slower-than-previously-expected earnings progression.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.